Taiwan cobra cardiotoxin III inhibits Src kinase leading to apoptosis and cell cycle arrest of oral squamous cell carcinoma Ca9-22 cells

被引:28
作者
Chien, Ching-Ming [1 ]
Chang, Shang-Yu [1 ]
Lin, Kuei-Li [1 ]
Chiu, Chien-Chih [2 ]
Chang, Long-Sen [3 ,4 ]
Lin, Shinne-Ren [1 ,4 ]
机构
[1] Kaohsiung Med Univ, Dept Med & Appl Chem, Kaohsiung 807, Taiwan
[2] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung 807, Taiwan
[3] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan
[4] Natl Sun Yat Sen Univ, Kaohsiung Med Univ, Joint Res Ctr, Kaohsiung 804, Taiwan
关键词
Akt; Ca9-22; cells; CTX III; PI3; K; Src; STAT; GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; PROTEIN-TYROSINE KINASES; NAJA-NAJA-ATRA; SIGNALING ACTIVATION; DOWN-REGULATION; FAMILY; HEAD; NECK; PATHWAYS;
D O I
10.1016/j.toxicon.2010.05.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiotoxin III (CTX III), a basic polypeptide with 60-amino acid residues isolated from Naja naja atra venom, has been reported to have cytotoxic activity CTX III exerted cytotoxicity with the S-phase cell cycle arrest, correlated with a marked decrease in the expression levels of cyclin A, cyclin B, and cyclin-dependent kinase 1 (CDK1), and apoptosis, accompanied with Bax and Bad up-regulation, and the down-regulation of Bcl-2, p-Bad, and X-linked inhibitor of apoptosis (XIAP) with cytochrome c release and sequential activation of caspase-9 and caspase-3 in Ca9-22 cells. Mechanistic studies showed that CTX III suppressed the phosphorylation of Src, EGFR, STAT3, STAT5, Akt, and activation of PI3 K (p110) Moreover, Src inactivation was observed earlier than that of the EGFR and the Src inhibitor PP2 suppressed the levels of phospho-EGFR, phospho-STAT3, phospho-STAT5, phospho-Akt, and PI3 K(p110). The PP2 also caused the S-phase arrest and apoptosis, and led to down-regulation of Bcl-2, p-Bad, XIAP, cyclin A. cyclin B, and CDK1, and up-regulation of Bax and Bad, similar to that observed in CTX III treatment. Taken together, these results indicate that CTX III induces apoptosis and S-phase arrest in Ca9-22 cells via concomitant inactivation of the Src, EGFR, STAT3, STAT5, PI3 K(p110), and Akt signaling pathways. (C) 2010 Elsevier Ltd. All rights reserved
引用
收藏
页码:508 / 520
页数:13
相关论文
共 42 条
[1]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[2]  
Ang KK, 2002, CANCER RES, V62, P7350
[3]   The Bcl-2 protein family [J].
Antonsson, B ;
Martinou, JC .
EXPERIMENTAL CELL RESEARCH, 2000, 256 (01) :50-57
[4]  
ARTEAGA CL, 2002, SEMIN ONCOL, V29, pS3, DOI DOI 10.1053/SONC.2002.35642
[5]   Src family kinases as potential therapeutic targets for malignancies and immunological disorders [J].
Benati, Daniela ;
Baldari, Cosima T. .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (12) :1154-1165
[6]   c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function [J].
Biscardi, JS ;
Maa, MC ;
Tice, DA ;
Cox, ME ;
Leu, TH ;
Parsons, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) :8335-8343
[7]   Tyrosine kinase signalling in breast cancer - Epidermal growth factor receptor and c-Src interactions in breast cancer [J].
Biscardi, JS ;
Ishizawar, RC ;
Silva, CM ;
Parsons, SJ .
BREAST CANCER RESEARCH, 2000, 2 (03) :203-210
[8]   Taiwan cobra cardiotoxins induce apoptotic death of human neuroblastoma SK-N-SH cells mediated by reactive oxygen species generation and mitochondrial depolarization [J].
Chen, Ku-Chung ;
Chiou, Yi-Ling ;
Kao, Pei-Hsiu ;
Lin, Shinne-Ren ;
Chang, Long-Sen .
TOXICON, 2008, 51 (04) :624-634
[9]   Apoptosis of human hepatocellular carcinoma cell (HepG2) induced by cardiotoxin III through S-phase arrest [J].
Chen, Xingyong ;
Lv, Ping ;
Liu, Jing ;
Xu, Kangsen .
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 2009, 61 (04) :307-315
[10]   Involvement of both endoplasmic reticulum- and mitochondria-dependent pathways in cardiotoxin III-induced apoptosis in HL-60 cells [J].
Chien, Ching-Ming ;
Yang, Sheng-Huei ;
Chang, Long-Sen ;
Lin, Shinne-Ren .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2008, 35 (09) :1059-1064